Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel
group, double-blind, superiority trial of vasopressin and methylprednisolone during adult
in-hospital cardiac arrest. There will be ten enrolling sites in Denmark. 492 adult patients
with in-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled.
The primary outcome is return of spontaneous circulation and key secondary outcomes include
survival at 30 days and survival at 30 days with a favorable neurological outcome.